Kindred Biosciences, Inc. is a biopharmaceutical firm dedicated to the advancement of biological therapies specifically for companion animals. The company maintains an extensive pipeline of innovative biologics, spanning diverse therapeutic categories, underpinned by a robust intellectual property portfolio. Key development programs include treatments for canine atopic dermatitis, utilizing both interleukin-31 and interleukin-4R, as well as KIND-030 to combat parvovirus in dogs. Additionally, KIND-510a targets non-regenerative anemia in cats, while an anti-TNF antibody is being developed for canine inflammatory bowel disease. Further candidates within its biologics portfolio are also under investigation. Established in 2012, Kindred Biosciences is headquartered in Burlingame, California.


Net sales
Gross margin
Net income